TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05252260

Intervention type: OTHER
Group type: OTHER
Intervention: Low level laser therapy (LLLT)
Description: Vestibuloplasty surgery was performed via diode laser. Following, LLLT was applied in continuous wave mode for 1 minute without contacting the tissue, using a phototherapy probe (power output, 0.5W; total energy of 6 J / cm²) at a distance of 1-2 mm from the tissue. LLLT was repeated immediately after the surgery, on the 1st, 3rd and 7th days
Study: NCT02183103

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: meloxicam rapid release tablet, 12mg, UH AC62MU

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: meloxicam rapid release tablet, 12mg, UH AC62MU
Study: NCT04513158

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent Plasma
Description: Plasma obtained from individuals previously diagnosed with SARS-CoV-2 (COVID-19) is administered to hospitalized patients meeting inclusion/exclusion criteria and have provided informed consent.
Study: NCT04281238

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga group
Description: Yoga training 3 days a week for 8 weeks. In addition to this, home exercises 5 days a week for 8 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: Home exercises 5 days a week for 8 weeks
Study: NCT02071303

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Celecoxib 200mg will be given to 70 women before the procedure.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo will be given to 70 women before the procedure.
Study: NCT05404594

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Maternal vocal contact
Description: Two consecutive venipuncture (order randomly balanced) within a short period of time will be realized with and without the presence of the mother talking/singing to her VPI infant.~In this intervention group, the mother will be supported to talk or to sing to her infants during before and during the venipuncture.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maternal vocal contact
Description: Two consecutive venipuncture (order randomly balanced) within a short period of time will be realized with and without the presence of the mother talking/singing to her VPI infant.~In this intervention group, the mother will be supported to talk or to sing to her infants during before and during the venipuncture.
Study: NCT01074879

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein
Description: Dietary supplement after training

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk protein
Description: Dietary supplement after training

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrates
Description: Dietary supplement after training
Study: NCT00659763

Intervention type: OTHER
Intervention: Exclusion diagnosis
Description: Patient fulfill ROME III criteria No Alarmsignals Blood tests: FBC,CRP, ALAT, bilirubins, bas.phosphatases, Albumine, TSH, calcium, celiac screening, lactase gene test.~3 consecutive fecal samples for worm, ovaes and parasites Sigmoidoscopy with biopsy

Intervention type: OTHER
Intervention: Clinical diagnosis
Description: Patient fulfill ROME III criteria No Alarm signals Blood tests: FBC, CRP.
Study: NCT04043377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: injection of 68Ga-DOTATATE
Description: PET after injection of 68Ga-DOTATATE 2 MBq/kg (Max. 200 MBq); intra-venous; single injection, at M0 followed by a coronary CTA to localize the signal in coronary arteries Consultation and low-dose cardiac CT for coronary calcium scoring performed at M12 and M24 after inclusion.
Study: NCT01891994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Oral administration of eltrombopag 150mg/day (75 mg/day for East Asian ancestry) for 6 months
Study: NCT02372747

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delta-shaped anastomosis
Description: The patients in DS group underwent Delta-shaped anastomosis after TLDG.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Billroth II anastomosis
Description: The patients in B-II group underwent Billroth-II anastomosis after TLDG.
Study: NCT02319824

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous NY-ESO-1-specific CD8-positive T Lymphocytes
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Palliative Radiation Therapy
Description: Undergo palliative radiation therapy
Study: NCT02305394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine and propofol
Description: propofol 1.5 mg/kg and ketamine 0.3 mg/kg will be administered to participants separately by intravenous infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol and normal saline
Description: propofol 1.5 mg/kg and normal saline \[weight(kg)×0.3÷10\]ml will be administered to participants separately by intravenous infusion.
Study: NCT01126203

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SLT
Description: All eyes will be treated using a commercially available Q-switched Nd:YAG laser (Coherent Selecta 7000, Coherent Inc., Palo Alto , CA, USA) calibrated by the manufacturer. On the day of treatment, IOP will be measured, then one drop of Apraclonidine 1% or Brimonidine 0.2% and pilocarpine 1% or 2% will be instilled. Before the patient is seated at the laser slit-lamp system a proparacaine hydrochloride drop will be instilled in the eye to be treated. A Goldmann goniolens or a Latina SLT or any other goniolens will be placed on the eye to be treated with methyl cellulose 1%. The helium-neon aiming beam is focused onto the pigmented trabecular meshwork. SLT will be performed with approximately 50 applications, a 400um spot size with energies varying from 0.8-1.2 mjoules.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ALT
Description: All eyes will be treated using Ophthalas 532 Eyelite Laser Photocoagulator (Alcon Surgical, Dallas-Fort Worth, Texas, USA. On the day of treatment, IOP will be measured, then on the day of treatment, IOP will be measured, then one drop of Apraclonidine 1% or Brimonidine 0.2% and pilocarpine 1% will be instilled. Before the patient is seated at the laser slit-lamp system a proparacaine hydrochloride drop will be instilled in the eye to be treated. A Goldmann goniolens will be placed on the eye to be treated with methyl cellulose 1%. The aiming beam is focused onto the anterior portion of the pigmented trabecular meshwork. ALT will be performed to the superior or inferior 180 degrees with \~ 50 applications, a 50um spot size with energies varying from 400-700 mW with 0.1 second duration.
Study: NCT03338933

Intervention type: BEHAVIORAL
Intervention: magnetic resonance imaging (MRI)
Description: All subjects will undergo a baseline MRI and subjects in both alcohol groups (alcohol use disorder and combined alcohol and nicotine use disorder) will undergo a followup MRI 3 months after baseline.

Intervention type: BEHAVIORAL
Intervention: magnetic resonance imaging (MRI)
Description: All subjects will undergo a baseline MRI and subjects in both alcohol groups (alcohol use disorder and combined alcohol and nicotine use disorder) will undergo a followup MRI 3 months after baseline.

Intervention type: BEHAVIORAL
Intervention: magnetic resonance imaging (MRI)
Description: All subjects will undergo a baseline MRI and subjects in both alcohol groups (alcohol use disorder and combined alcohol and nicotine use disorder) will undergo a followup MRI 3 months after baseline.

Intervention type: BEHAVIORAL
Intervention: magnetic resonance imaging (MRI)
Description: All subjects will undergo a baseline MRI and subjects in both alcohol groups (alcohol use disorder and combined alcohol and nicotine use disorder) will undergo a followup MRI 3 months after baseline.
Study: NCT02911792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: SGLT2 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: SGLT2 inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Oral diabetes medicine that helps control blood sugar levels.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Oral diabetes medicine that helps control blood sugar levels.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glipizide 5 MG
Description: Oral diabetes medicine that helps control blood sugar levels.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glipizide 5 MG
Description: Oral diabetes medicine that helps control blood sugar levels.
Study: NCT02816996

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hand-holding
Description: Subject will have their hand held.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stress Ball
Description: Subject will be given a stress ball to hold.
Study: NCT01424124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHD001 dose level 1
Description: Tablet, three times daily / 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHD001 dose level 2
Description: Tablet, three times daily / 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Singulair
Description: Tablet, one times daily / 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, one times daily / 7 days
Study: NCT01778205

Intervention type: OTHER
Intervention: Observational
Study: NCT04230330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Nivolumab
Description: 240mg every 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Nivolumab
Description: Initial treatment dose is 240mg every 2 weeks for 4 doses. Dose changes to 360mg every 3 weeks when given with GDP/L-aspa. Maintenance treatment dose is 240mg every 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Gemcitabine
Description: 800mg/m2 on Days 1 and 8 every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Cisplatin
Description: 20mg/m2 on Day 1 to 4 every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV/PO Dexamethasone
Description: 10mg on Days 1 to 4 every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV L-asparaginase
Description: 6000 Units/m2 on Days 2 to 8 every 21 days
Study: NCT02906293

Intervention type: OTHER
Intervention: Abdominal acoustic measurement
Description: On Day 1 participants will record their intestinal rate at baseline fasting, pre-small meal, and upon completion of the meal. On Day 2 participants will record their intestinal rate at baseline fasting, pre-large meal, and upon completion of meal.
Study: NCT00397787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: Given PO
Study: NCT02596100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betrixaban

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betrixaban
Study: NCT03755947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib Oral Capsule \[Imbruvica\] Tablets 120 mg. Oral. 420mg/day, day 1 to 28, every 28 days. 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab Injection. Intravenous Solution \[Gazyva\] Parenteral. 1000 mg, day 1 of every cycle, every 28 days. 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax Oral Tablets \[Venclexta\] Tablets 100 mg. Oral. 400 mg/day. Day 1 to 28, every 28 days. 12 cycles.
Study: NCT01686477

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Unfortified Human donor Milk used to make up any shortfall in mother's own milk

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fortified Human donor Milk used to make up any shortfall in mother's own milk

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preterm Formula used when there is a shortfall in mother's own milk
Study: NCT03965091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fremanezumab
Description: Fremanezumab will be administered per dose and schedule specified in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fremanezumab
Description: Fremanezumab will be administered per dose and schedule specified in the arm description.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to fremanezumab will be administered per schedule specified in the arm description.
Study: NCT00151515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: minoxidil
Description: Topical 5% minoxidil foam, BID, for sixteen weeks
Study: NCT02655341

Intervention type: DEVICE
Intervention: Body Composition Monitoring
Description: using Fresenius device; two measurements before and after coronary intervention;

Intervention type: PROCEDURE
Intervention: Coronarography
Description: Preprocedural coronary arteriography is obtained after sterile preparation and draping of the patient, conscious sedation, infiltration of local anesthetic (lidocaine solution) at the femoral access site, placement of an arterial sheath in the femoral artery, and advancement of the renal guide catheter over a 0.035-in guidewire under fluoroscopic guidance. After the tip of the guide catheter is positioned at the ostium of the left coronary stem, an angiogram is obtained. After the guidewire is removed, the proximal end of the catheter is connected to a manifold, and 4-8 mL of contrast is manually injected during cineangiographic recording.

Intervention type: PROCEDURE
Intervention: Primary Percutaneous Coronary Intervention
Description: An intravenous antithrombotic agent, usually heparin, is administered before the clinician proceeds with angioplasty.

Intervention type: PROCEDURE
Intervention: Renal Angiography
Description: After the tip of the guide catheter is positioned at the ostium of the renal artery, an angiogram is obtained. After the guidewire is removed, the proximal end of the catheter is connected to a manifold, and 4-8 mL of contrast is manually injected during cineangiographic recording. This procedure is performed in the same time with primary PCI
Study: NCT04333498

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback on DBS Concentrations
Description: The study team will examine the feasibility and acceptability of a feedback system based on DBS concentration amounts.
Study: NCT02340325

Intervention type: DRUG
Group type: OTHER
Intervention: Acute Application of kynurenic acid cream
Description: Pouches containing 0.00% (placebo), 0.15%, 0.25%, 0.4% and 0.5% of FS2 will be randomly applied to an occlusive, transparent dressing (Tegaderm) and applied to each test area. The pouch order will be random, generated by the www.random.org list generator each application. The study team member applying the cream will randomly choose the application sites of different concentrations of the FS2 creams and mark the corresponding cream code name on a separate sheet. This study member will not be evaluating the results and the evaluating study member will be blinded to the randomization. Patients will be evaluated at 24 hours post application for skin reactions and adverse reactions by a blinded observer recorded. Before and after photographs will be taken.

Intervention type: DRUG
Group type: OTHER
Intervention: Chronic application of kynurenic acid cream
Description: Volunteers will be educated how to apply a pouch of cream to an occlusive, transparent dressing (Tegaderm) and place it on the test site every 24 hours for 30 days. The date and time of first application will be recorded. Baseline urine and serum measurements of drug concentration (presumed absent), as well as complete blood count, liver enzymes, blood urea nitrogen, and creatinine will be taken on Day 0 (the initial enrollment of each part). The volunteers will be seen in follow-up at day 1, day 5, day 15, and day 30
Study: NCT03950804

Intervention type: DRUG
Intervention: Eculizumab Injection
Description: Patients receive eculizumab as deemed necessary by the primary physician
Study: NCT00118287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: Given SC or IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: etanercept
Description: Given SC
Study: NCT03594838

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HCV viremia testing approaches
Description: Blood draw and HCV viremia testing is done at point of service (Intervention A) Blood draw at point of service and HCV viremia testing at a centralized laboratory (Intervention B)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HCV viremia testing approaches
Description: Blood draw and HCV viremia testing is done at point of service (Intervention A) Blood draw at point of service and HCV viremia testing at a centralized laboratory (Intervention B)
Study: NCT03690544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast 30mg
Description: Apremilast is an oral small-molecule inhibitor of phosphodiesterase (PDE) 4 that works intracellularly to modulate a network of pro-inflammatory and anti-inflammatory mediators. PDE 4 is a cyclic adenosine monophosphate (cAMP)-specific PDE and the dominant PDE in inflammatory cells. PDE4 inhibition elevates intracellular cAMP levels, which in turn down-regulates the inflammatory response by modulating the expression of TNF-alfa, IL-23, IL-17 and other inflammatory cytokines. Cyclic AMP also modulates levels of anti-inflammatory cytokines such as IL-10. Apremilast has immunomodulatory activity and, therefore, has the potential to be effective in the treatment of RAS.
Study: NCT04392804

Intervention type: PROCEDURE
Intervention: scaling and root planing
Description: one appointment for scaling and root planing of selected periodontal pockets, with periodontal curette (HuFriedy, Chicago, IL, USA), rinsing with saline solution

Intervention type: PROCEDURE
Intervention: scaling and root planing
Description: one appointment for scaling and root planing of selected periodontal pockets, with periodontal curette (HuFriedy, Chicago, IL, USA), rinsing with saline solution

Intervention type: PROCEDURE
Intervention: scaling and root planing
Description: one appointment for scaling and root planing of selected periodontal pockets, with periodontal curette (HuFriedy, Chicago, IL, USA), rinsing with saline solution
Study: NCT00957710

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Errorless learning
Description: Language testing,20 sessions of language therapy, and 2 neuroimaging sessions for participants with progressive aphasia Language testing and 1 imaging session for healthy controls
Study: NCT02467816

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SmartMeal application
Description: The SmartMeal application is a smartphone application that will allow students to pre-order school meals, receive nutrition information about school meals, and provide feedback about school meals to Student Nutrition Services.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distributed points of sale
Description: To increase points of sale for school meals (outside the cafeteria), school meals will be sold at hot and cold mobile food carts and vending machines throughout the school.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Staff wellness curriculum
Description: A wellness curriculum will be implemented that encourages teachers and staff members to eat school meals and promote them to students.
Study: NCT04254211

Intervention type: OTHER
Intervention: NLR
Description: neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR)
Study: NCT02787291

Intervention type: DEVICE
Group type: OTHER
Intervention: Ellipse VR ICD and Durata/Optisure lead
Description: Non-diagnostic MRI Scan sequence of head and chest
Study: NCT01246167

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Philos
Description: Conservative treatment versus Philos locking plate in 2 part fracture group.~Conservative treatment versus Philos locking plating versus Epoca prosthesis in MFF group.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Epoca
Description: Conservative treatment versus Philos locking plate versus Epoca fracture prosthesis in MFF group

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Conservative control group
Study: NCT03231176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varlitinib
Description: oral tablets, twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: oral tablets, twice daily for 2 weeks followed by a 1-week rest period in 3-week cycles
Study: NCT00484159

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency denervation of medial branches
Description: Radiofrequency of medial branches that innervate the lumbar facet joints

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency denervation of medial branches
Description: Radiofrequency of medial branches that innervate the lumbar facet joints

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency denervation of medial branches
Description: Radiofrequency of medial branches that innervate the lumbar facet joints

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Description: Diagnostic medial branch block with 0.5% bupivacaine. Blocking the nerves that innervate the facet joints with a long-acting local anesthetic.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Description: Diagnostic medial branch block with 0.5% bupivacaine. Blocking the nerves that innervate the facet joints with a long-acting local anesthetic.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% lidocaine
Description: Diagnostic medial branch block with 2% lidocaine. Blocking the nerves that innervate the facet joints with a short-acting local anesthetic.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency denervation
Description: Radiofrequency lumbar facet denervation without a diagnostic block

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency denervation
Description: Radiofrequency lumbar facet denervation only if positive response to 2 diagnostic blocks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency denervation
Description: Lumbar facet radiofrequency denervation if positive response to a single diagnostic facet block

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency denervation
Description: Radiofrequency lumbar facet denervation without a diagnostic facet block.
Study: NCT00446875

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Administration of oral Sucrose
Description: Participants received oral sucrose 2 minutes prior to the combind DTaP, IPV, and Hep B vaccine.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Administration of oral Placebo
Description: Participants received Placebo 2 minutes prior to the combind DTaP, IPV, and Hep B vaccine.